Cipla Share Price Saw a Drop of Over ~3% After Eli Lilly Partnership

On October 24, 2025, Cipla share price fell over 3%, reaching a day low of ₹1,590.00 at 10:30 AM, after opening at ₹1,639.95 on BSE. The fall in Cipla share price follows the announcement that the Mumbai-based drugmaker has partnered with US pharma giant Eli Lilly to market Lilly’s blockbuster weight-loss drug in India under a new brand name.

Deal Details: Manufacturing by Eli Lilly, Marketing by Cipla

Under the agreement, Eli Lilly will manufacture the drug, while Cipla will market it as Yurpeak, the companies said on Thursday. Yurpeak will be offered as a once-weekly, pre-filled injector pen, similar to Lilly’s Mounjaro Kwikpen, allowing healthcare providers to tailor treatment plans to individual patients. The medication will be available in six doses, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and will be priced on par with Mounjaro.

Also Read: Cipla’s New Move in Diabetes Segment with Eli Lilly’s Tirzepatide Launch

Background on Mounjaro and Tirzepatide

Eli Lilly had launched Mounjaro in India in March for diabetes and obesity, initially in 2.5 mg and 5 mg vials, and received approval for the Kwikpen device in June. The product has seen more than double the sales since its launch. The active ingredient, tirzepatide, is a GLP-1 receptor agonist, which helps regulate blood sugar and slow digestion, keeping patients feeling fuller for longer.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.